Tech Company Financing Transactions
NorthLinks Bio Funding Round
NorthLinks Bio, operating out of Boston, secured $34 million in funding from RA Capital Management.
Transaction Overview
Company Name
Announced On
6/23/2026
Transaction Type
Venture Equity
Amount
$34,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to advance its lead intranasal prophylactic antiviral candidate toward Phase 2b readiness, expand its proprietary glycan-targeted platform, support ongoing manufacturing operations, and establish its primary corporate infrastructure in the United States.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
200 Berkeley Street, 19th Floor
Boston, MA 02116
USA
Boston, MA 02116
USA
Phone
Undisclosed
Website
Email Address
Overview
NorthLinks Bio is a clinical-stage biopharmaceutical company developing HEX17, a first-in-class intranasal antiviral designed to provide broad protection against respiratory viruses at the point of entry. Our simple, preventative approach has been shown to protect against influenza in a Phase 2 human challenge study.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Fanny Cavalié
VP - Bus. Development
Elnaz Menhaji-Klotz
VP - R & D
Alexander Rumyantsev
VP - R & D
Mingkui Zhou
Browse more venture capital transactions:
Prev: 6/23/2026: Sophia Space venture capital transaction
Next: 6/23/2026: Sherlocks AI venture capital transaction
Share this article
News on VC Transactions
We do our best to document every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs